Neuroprotective antioxidants from marijuana

Annals of the New York Academy of Sciences

Volumn 899, Issue , 2000, Pages 274-282

  Hampson, A J ^a,e   Grimaldi, M ^b   Lolic, M ^c   Wink, D ^d   Rosenthal, R ^c   Axelrod, J ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d Radiation Oncology Branch   (United States)

^e Cortex Pharmaceutical Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR AGONIST; CANNABIS; GLUTAMIC ACID; HYDROPEROXIDE; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; NEUROTRANSMITTER; PSYCHOTROPIC AGENT; TETRAHYDROCANNABINOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN CELL; BRAIN ISCHEMIA; CONFERENCE PAPER; CONTROLLED STUDY; IN VITRO STUDY; MALE; NERVE CELL CULTURE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; POTENTIOMETRY; RAT;

EID: 0012352186     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06193.x     Document Type: Conference Paper

References (17)

1. 1. WELCH, S.P. & D.L. STEVENS. 1992. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. 262(1): 8-10.
2. 2. MERRITT, J.C., W.J. CRAWFORD, P.C. ALEXANDER, A.L. ANDUZE & S.S. GELBART. 1980. Effect of marihuana on intraocular and blood pressure in glaucoma Ophthalmol. 87(3): 222-228.
3. 3. ABRAHAMOV, A. & R. MECHOULAM. 1995 An efficient new cannabinoid antiemetic in pediatric oncology Life Sci. 56(23-24): 2097-2102.
4. 4. CIANI, E., L. GRONENG, M. VOLTATTORNI, V. ROLSETH, A. CONTESTABILE & R.E. PAULSEN. 1996. Inhibition of free radical production or free radical scavenging from the excitotoxic cell death mediated by glutamate in cultures of cerebellar granule neurons. Brain Res. 728: 1-6.
5. 5. MACGREGOR, D.G., M.J. HIGGINS, P.A. JONES, W.L. MAXWELL, M.W. WATSON, D.I. GRAHAM & T.W. STONE. 1996. Ascorbate attenuates the systemic kainate-induced neurotoxicity in the rat hippocampus Brain Res 727(1-2): 133-144.
6. 6. SKAPER, S.D., A. BURIANI, R. DAL TOSO, I.L. PETRELL, L. ROMANELLO, L. FACCI & A. LEON. 1996. The aliamide, palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed, postglutamate paradigm of excitotoxic death in cerebellar granular neurons. Proc. Natl. Acad. Sci. USA 93: 3984-3989.
7. 7. HAMPSON, A.J., L.M. BORNHEIM, M. SCANZIANI, C.S. YOST, A.T. GRAY, B.M. HANSEN, D.J. LEONOUDAKIS & P.E. BICKLER. 1998. Dual Effects of Anandamide on NMDA Receptor-Mediated Responses and Neurotransmission J. Neurochem. 70: 671-676.
8. 8. TWITCHELL, W., S. BROWN & K. MACKIE. 1997. Cannabinoids inhibit N-and P/Q-type calcium channels in cultured rat hippocampal neurons J. Neurophysiol. 78 (1):43-50.
9. 9. ESHHAR, N., S. STRIEM, R. KOHEN, O. TIROSH & A. BIEGON. 1995. Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur. J. Pharmacol. 283(1-3): 19-29
10. 10. DEVANE, W.A., F.A. DYSARZ, M.R. JOHNSON, L.S. MELVIN & A.C. HOWLETT. 1988. Determination and characterization of a cannabinoid receptor in rat. Mol. Pharmacol. 34(5): 605-613.
11. 11. LEDENT, C., O. VALVERDE, G. COSSU, F. PETITET, J.F. AUBERT, F. BESLOT, G.A. BÖHME, A. IMPERATO, T. PEDRAZZINI,. B.P. ROQUES, G. VASSART, W. FRATTA & M. PARMENTIER. 1999. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401-404
12. 12. THOMPSON, J.A., J.L. BOLTON & A.M. MALKINSON. 1991. Relationship between the metabolism of butylated hydroxytoluene (BHT) and lung tumor promotion in mice Exp. Lung Res. 172(2): 439-453.
13. 13. LINDENSCHMIDT, R.C., A.F. TRYKA, M.E. GOAD & H.P. WITSCHI. 1986. The effects of dietary butylated hydroxytoluene on liver and colon tumor development in mice. Toxicology 38(2): 151-160.
14. 14. AUER, R.N. 1994. Assessing structural-changes in the brain to evaluate neurotoxicological effects of NMDA receptor antagonists. Psychopharmacol Bull. 30(4): 585-591.
15. 15. NEUMEYER, J.L. & R.A. SHAGOURY. 1971. Chemistry and pharmacology of marijuana. J. Pharm. Sci. 60(10):1433-1457.
16. 16. CUNHA, J.M., E.A. CARLINI, A.E. PEREIRA, O.L. RAMOS, C. PIMENTEL, R. GAGLIARDI, W.L. SANVITO, N. LANDER & R. MECHOULAM. 1980. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21(3): 175-185.
17. 17. CONSROE, P., J. LAGUNA, J. ALLENDER, S. SNIDER, L. STERN, K.R. SANDY, K. KENNEDY & K. SCHRAM. 1991. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol. Biochem. Behav. 40(3): 701-708.